Publication date: December 2026 Source: ESMO Gastrointestinal Oncology, Volume 14 Author(s): J.P. Spano, J. Capdevila, F. Van Fraeyenhove, S. Lonardi, F. Morano, M. Guillot Morales, P. Rochefort, M. Ducreux, A. Gordon, L. Evesque, E. Kim, M. Jones, X. Xu, M.C. Munteanu, A. Vozy, D.C. Gilbert
Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆. // ESMO Gastrointestinal Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S294981982600141X?dgcid=rss_sd_all
Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆. ESMO Gastrointestinal Oncology. https://www.sciencedirect.com/science/article/pii/S294981982600141X?dgcid=rss_sd_all
“Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆.” ESMO Gastrointestinal Oncology.
@article{article93715,
title = {Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆},
journal = {ESMO Gastrointestinal Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S294981982600141X?dgcid=rss_sd_all}
}